knowledge -WSS

knowledge

author：leisure time 2025-10-02 19:19:49 - browse：8834

A glass office building of MassMutual with its sign on the top left — insurance coverage from STAT — Adobe

One of the country’s biggest life insurers is venturing into genetic testing, an area that’s historically been a minefield for that industry, in a purported effort to keep its members alive longer.

MassMutual announced Tuesday that it’s offering many of its 4.2 million policyholders free genetic risk assessments for eight common diseases, like heart disease, type 2 diabetes, and breast cancer. The Springfield, Mass.-based insurer hopes that when people learn they carry a genetic predisposition, they’ll take action to lower their risk through diet, exercise, and getting regular screenings.

Viewed one way, it’s a win-win: The longer its members live, the longer MassMutual can collect and invest their premiums without paying out.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the financial innards of our health care system — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Jerome Adams on the need for new antivirals for Covid
Next article： Readout LOUD podcast, live from the STAT Breakthrough Summit East

focus

WSS

First U.S. drug developed to treat liver disease MASH is approved

Amid AI frenzy, a top HHS official's quest to create safeguards

Biotech investment managers search for lucrative opportunities

Texas board proposes rules on abortion law emergency exemption

Acadia's Nuplazid fails as schizophrenia medicine in Phase 3 study

Change Healthcare outage fallout shows need for new oversight

leisure time

knowledge

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the financial innards of our health care system — by subscribing to STAT+.

Wikipedia

Trump demands the U.S. pay no more for drugs than other countries … again

Mirador, a new biotech startup, launches with $400 million

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

President Biden's budget: Here's what you might have missed

Medical leaders decry Supreme Court decision on affirmative action

Bring on the sabbaticals for nurses

New air purifier tech could be key to improving indoor air quality

Acadia's Nuplazid fails as schizophrenia medicine in Phase 3 study

Bright Health sells Medicare Advantage business to Molina

CRISPR technology availability, affordability needs to be expanded

knowledge

'Patient friction coefficient' can gauge a clinical trial's patient burden

Amid AI frenzy, a top HHS official's quest to create safeguards

'Patient friction coefficient' can gauge a clinical trial's patient burden

This gene therapy has record $4.25 million price. It's saved children.

Medicare Advantage insurers pressure Biden for bigger payments

Acadia's Nuplazid fails as schizophrenia medicine in Phase 3 study

leisure time

focus

hotspot

focus